Ascendis Pharma A/S (ASND) fair value analysis
Nasdaq · Updated 2026-09-07
Ascendis Pharma A/S is a biopharmaceutical company that develops and commercializes medications using its TransCon technology platform to treat endocrine and other serious diseases. The company operates internationally with operations in multiple countries including Denmark, where it is headquartered, and the United States.
Valuation status
Awaiting full valuationASND does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under our standards — we require at least six validated trailing price-to-earnings windows before publishing one. TickrTrends re-evaluates every covered stock weekly; a verdict publishes automatically once enough validated history accumulates.
- Last price
- $243.45
- Sector
- Healthcare
- 12-month range
- $200.98–$267.79
Derived indicators
Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.
- Quality grade
- C-
- Leverage
- Low
- RSI zone
- Neutral
- 50/200-day trend
- Mixed
- 52-week position
- The upper-middle quarter of its range
What our data shows for ASND
- Shares are trading in the middle of their 12-month price range of $200.98–$267.79.
- The 14-day relative strength index sits at a neutral 69.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for ASND
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
How Forward Fair Value works
TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.
Recent ASND news
TickrTrends' derived news-sentiment signal for ASND is currently leaning positive, computed from recent coverage.
- Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026 (manilatimes.net, 2026-09-07)
TickrTrends take: Ascendis Pharma operates in a sector where clinical data presentations can materially influence investor perception of pipeline value, particularly for rare disease programs where successful trial results may support premium valuations. TickrTrends is currently awaiting full valuation metrics for ASND, meaning the market has not yet settled on a clear consensus regarding the company's worth. Upcoming endocrinology data disclosures at major conferences represent the type of clinical milestones that typically drive valuation reassessment, so investors monitoring ASND should track whether these presentations move the needle on pipeline confidence and addressable market sizing. - BioMarin (BMRN) Secured 20% U.S. Royalties on Yuviwel. Is Monetizing a Rival Better than Blocking It? (finance.yahoo.com, 2026-09-04)
TickrTrends take: BioMarin's decision to monetize a competing therapy through royalties rather than block it highlights a strategic shift in the pharmaceutical industry toward partnership-based revenue models. For ASND investors awaiting full valuation context, this development underscores how healthcare companies are increasingly generating returns from rival products, which could influence how competitors and investors evaluate ASND's own pipeline and licensing opportunities. The precedent set by larger players accepting royalty streams from alternatives may reshape expectations around ASND's potential partnerships and the valuation multiples applied to its revenue-generating assets. - Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes (finance.yahoo.com, 2026-08-31)
TickrTrends take: Ascendis Pharma's resolution of global patent disputes with BioMarin removes a significant source of litigation risk that could have affected the company's financial resources and operational focus going forward. With this uncertainty cleared, investors evaluating ASND should monitor whether the company can now redirect attention and capital toward its pipeline development and commercialization efforts, which would be relevant factors for establishing a complete valuation once TickrTrends completes its analysis. The settlement's terms and any financial implications will be important to track as they may influence the company's cash position and growth trajectory in the Healthcare sector.
What people are saying
Follow the ASND conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is ASND stock undervalued?
ASND does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is ASND's TickrTrends verdict?
ASND is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
Is ASND overbought or oversold?
ASND's 14-day RSI is in neutral territory - neither overbought nor oversold.